Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments, increasing biosimilar adoption, and implementing policies that reduce financial disparities and improve long-term patient outcomes.
Making the cost of inflammatory bowel disease (IBD) care sustainable requires improving access to cost-effective treatments, increasing biosimilar uptake, and implementing multidisciplinary care strategies to reduce both direct and indirect expenses, according to a recent review.
Biosimilars offer cost-saving potential for patients with IBD but face adoption barriers in the US, including delayed approvals, patent thickets, and payer incentives favoring originators. | Image credit: Aliaksandr Marko - stock.adobe.com
The review, published in Clinical Gastroenterology and Hepatology, encompassed the current landscape of IBD care, highlighting challenges with achieving cost sustainability in the space as well as access and affordability disparities.
Direct costs associated with IBD care include expenses related to physician visits, emergency care, hospitalizations, surgeries, diagnostics, medications, and supportive therapies. The annual per-person cost of these services varies by region, with estimates around $9000 to $12,000 in high-income countries, between $1000 and $4000 in middle-income nations, and $200 to $800 in low-income countries.
Although hospitalization costs historically dominated IBD expenses, the rise of biologic therapies has shifted the cost burden to medications, particularly in the US, where drug prices remain significantly higher due to market dynamics and a lack of regulation. Despite the rise in effective treatments correlating with reduced hospitalizations, the cost per admission continues to rise, driven by inflation, disease complexity, and the need for newer therapies.
“Addressing the increasing financial burden of IBD requires a comprehensive approach that tackles disparities, enhances access to cost-effective therapeutics, and promotes collaborative efforts across health care systems. Embracing innovative strategies can pave the way for personalized, cost-effective care accessible to all individuals with IBD, ensuring better outcomes and sustainability,” the authors wrote.
Socioeconomic and racial inequities lead to delayed treatment, higher hospitalizations, and worse outcomes. Geographic disparities and insurance barriers further limit access to biologics, increasing health care costs.
Early biologic therapy can reduce long-term complications, but high costs and restrictive insurance policies hinder widespread use. Countries with robust health care policies, like Denmark, have achieved cost savings through early biologic use, while the US faces inefficiencies due to limited price negotiations and fragmented insurance systems.
Biosimilars offer cost-saving potential but face adoption barriers in the US, including delayed approvals, patent thickets, and payer incentives favoring originators. Europe has successfully integrated biosimilars and reduced costs, but US uptake remains inconsistent between markets 10 years in, with the rheumatic and gastroenterology spaces among those where biosimilars are struggling.2
To improve cost sustainability, reforms must ensure equitable access, promote biosimilar adoption, and streamline insurance policies to support high-value care.1 Addressing disparities and optimizing treatment strategies will be key to controlling IBD health care costs.
References
1. Burisch J, Claytor J, Hernandez I, Hou JK, Kaplan GG. The cost of inflammatory bowel disease care: how to make it sustainable. Clin Gastroenterol Hepatol. 2025;23(3):386-395. doi:10.1016/j.cgh.2024.06.049
2. Jeremias S. From Amjevita to Zarxio: a decade of US biosimilar approvals. The Center for Biosimilars®. March 6, 2025. Accessed March 11, 2025. https://www.centerforbiosimilars.com/view/from-amjevita-to-zarxio-a-decade-of-us-biosimilar-approvals
Evidence Grows for Upadacitinib in Managing Moderate to Severe UC
May 12th 2025Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term trials and real-world data, with findings reinforced by new results presented at Digestive Disease Week 2025.
Read More
Updated Guidelines Aim to Improve GERD Diagnosis and Treatment
May 6th 2025The American Society for Gastrointestinal Endoscopy has issued new guidelines for diagnosing and managing gastroesophageal reflux disease (GERD), with updated recommendations on endoscopy use, lifestyle changes, and endoscopic treatments like transoral incisionless fundoplication.
Read More
Upadacitinib Shows Promise for Hard-to-Treat Crohn Disease
April 23rd 2025Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies, offering a potential second-line treatment option with a manageable safety profile.
Read More
The Hidden Connection Between Air Quality and Gut Health
April 21st 2025Long-term exposure to multiple air pollutants may silently wreak havoc on your gut, significantly increasing the risk of gastrointestinal diseases and underscoring the urgent need for public health policies that clean the air we breathe and protect our digestive health.
Read More